Cigna Group: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Oct 31, 2024 and accepted by EDGAR at Oct 31, 2024, 13:36 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $63.69bn | us-gaap:Revenues |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $181.47bn | us-gaap:Revenues |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $47.56bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $133.49bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $3.59bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $10.98bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | $2.58bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | $7.24bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $367.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | $1.02bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | $825.0m | us-gaap:ProfitLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | $2.24bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | $2.63 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | $7.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | $2.65 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | $7.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 281,396,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 285,042,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | $5.15bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months2024-01-01 to 2024-09-30 | $1.18bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2024-01-01 to 2024-09-30 | $5.01bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-30 | $5.89bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $49.22bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $157.64bn | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $57.06bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $115.34bn | us-gaap:Liabilities |
| Current portion of debt | At period end2024-09-30 | $2.57bn | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2024-09-30 | $1.64bn | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2024-09-30 | $42.09bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739940-24-000033. Last ingested by Listed: Nov 5, 2026, 13:13 ET. Listed shows no prices and gives no investment advice.